Luitpold Pharmaceuticals, Inc. Announces Temporary Suspension of Distribution and Manufacture of Drug Products

As a result of a recent inspection and a follow-up meeting with FDA, Luitpold agreed to suspend distribution of any drug product manufactured at its Shirley, New York facility.

Luitpold Pharmaceuticals, Inc. announced that it has temporarily suspended distribution of all of its drug products manufactured at its Shirley, New York facility and marketed by its American Regent, Inc. subsidiary and Animal Health Division.

As a result of a recent inspection and a follow-up meeting with FDA on April 14, 2011, Luitpold agreed to temporarily suspend distribution of any drug product manufactured at its Shirley, New York facility. (It had previously suspended the manufacture of its drug products on its own initiative).

This action does not affect products manufactured at its PharmaForce Inc. subsidiary, including its Betamethasone Sodium Phosphate and Betamethasone Sodium Acetate Injectable Suspension, USP. Osteohealth and Regency Therapeutics Division products,